ATAI
NASDAQ
$7.19
ATAI Life Sciences N.V. (ATAI)
ATAI Life Sciences is a pharmaceutical company that is developing psychedelics, other hallucinogens, entactogens, and related drugs for treatment of psychiatric conditions. It was founded in 2018 and is headquartered in Berlin, Germany.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $12.59 (+75.10%)
Market Cap
$1.96B
Free Cash Flow Yield
-5.29%
Beta (5Y)
1.41
Price Chart
Valuation
Market Cap$1.96B
P/S565.76
P/B10.51
Profitability
Total Revenue (TTM)$4.09M
Gross Profit (TTM)-$55M
EBITDA-$643M
Operating Margin-3239%
EPS-$1.82
Financial Health
Debt-to-Equity84%
Free Cash Flow Yield-5.29%
Growth & Risk
Beta (5Y)1.41
Sharpe Ratio1.47